📖

Progressive Supranuclear Palsy (PSP) Treatment Guide

wiki page Created: 2026-04-02 13:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-progressive-supranucle
Related Entities
therapeutics-progressive-supranuclear-psp-treatment
Metadata
slugtherapeutics-progressive-supranuclear-psp-treatment
entity_typetherapeutic
kg_node_idNone
Linked Artifacts (112)
mentions🧪TREM2-mediated microglial tau clearance enhancement70%
related🧫Animal Model Comparison for Neurodegenerative Disease Therap70%
related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#70%
related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&70%
related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag70%
related🧫Neural Oscillation Dysfunction Validation in Parkinson'70%
related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#70%
related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin70%
related🧫Protein Aggregation Kinetic Validation Results70%
related🧫Purinergic Signaling Dysfunction Validation in Parkinson70%
related🧫Regulated Necrosis Validation Study in Parkinson's Dise70%
related🧫Stress Granule Dysfunction Validation in Parkinson's Di70%
related🧫Experiment Validation: In vitro ThT Assay70%
related🧫4R-Tau Targeting Therapies for PSP and CBS70%
related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri70%
related🧫Brainstem Circuit Modulation for PSP70%
related🧫Levodopa Response Determinants in PSP — Biomarker-Guided Pre70%
related🧫PSP and CBS Biomarker Validation Study70%
related🧫Tau Pathology Initiation Zone Identification70%
related🧫Tau Spreading Network Mapping via Spatial Transcriptomics in70%
related🧫Animal Model Comparison for Neurodegenerative Disease Therap70%
related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#70%
related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&70%
related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag70%
related🧫Neural Oscillation Dysfunction Validation in Parkinson'70%
related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#70%
related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin70%
related🧫Protein Aggregation Kinetic Validation Results70%
related🧫Purinergic Signaling Dysfunction Validation in Parkinson70%
related🧫Regulated Necrosis Validation Study in Parkinson's Dise70%
related🧫Stress Granule Dysfunction Validation in Parkinson's Di70%
related🧫Experiment Validation: In vitro ThT Assay70%
related🧫4R-Tau Targeting Therapies for PSP and CBS70%
related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri70%
related🧫Brainstem Circuit Modulation for PSP70%
related🧫Levodopa Response Determinants in PSP — Biomarker-Guided Pre70%
related🧫PSP and CBS Biomarker Validation Study70%
related🧫Tau Pathology Initiation Zone Identification70%
related🧫Tau Spreading Network Mapping via Spatial Transcriptomics in70%
mentions🧪TREM2 Conformational Stabilizers for Synaptic Discrimination65%
related🧪TREM2-mediated microglial tau clearance enhancement63%
mentions🔬What are the mechanisms underlying 4r-tau strain-specific sp60%
mentions🔬PSP and CBD both involve 4R-tau but produce distinct neuropa60%
related🧫s:** - Single-cell RNA-seq to measure editing efficiency acr60%
related🧫Metabolic Pathway-Targeted Therapy in ALS60%
related🧫ALS Progression Rate Heterogeneity — mechanism and biomarker60%
related🧫ALS Regional Onset and Spread: Network-Level Staging Model60%
related🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk60%
related🧫Blood Biomarker vs Tau PET for Treatment Monitoring60%
related🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT60%
related🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study60%
related🧫Environmental Exposure Causal Attribution in ALS — Experimen60%
related🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio60%
related🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design60%
related🧫N-of-1 Clinical Trial Design for CBS/PSP60%
related🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers60%
related🧫Pre-Symptomatic Detection and Intervention Timing in Genetic60%
related🧫Progranulin Replacement Therapy for FTD — Vector Development60%
related🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD60%
related🧫Sleep and Respiratory Network Interaction in ALS — Experimen60%
related🧫TDP-43 PET Ligand Development for FTD and ALS60%
related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des60%
related🧪TREM2 Conformational Stabilizers for Synaptic Discrimination59%
related🔬What are the mechanisms underlying 4r-tau strain-specific sp54%
related🔬PSP and CBD both involve 4R-tau but produce distinct neuropa54%
related🧫s:** - Single-cell RNA-seq to measure editing efficiency acr54%
related🧫Metabolic Pathway-Targeted Therapy in ALS54%
related🧫ALS Progression Rate Heterogeneity — mechanism and biomarker54%
related🧫ALS Regional Onset and Spread: Network-Level Staging Model54%
related🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk54%
related🧫Blood Biomarker vs Tau PET for Treatment Monitoring54%
related🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT54%
related🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study54%
related🧫Environmental Exposure Causal Attribution in ALS — Experimen54%
related🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio54%
related🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design54%
related🧫N-of-1 Clinical Trial Design for CBS/PSP54%
related🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers54%
related🧫Pre-Symptomatic Detection and Intervention Timing in Genetic54%
related🧫Progranulin Replacement Therapy for FTD — Vector Development54%
related🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD54%
related🧫Sleep and Respiratory Network Interaction in ALS — Experimen54%
related🧫TDP-43 PET Ligand Development for FTD and ALS54%
related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des54%
mentions🧫Functional validation of trehalose effects on misfolded prot50%
mentions🧫Trehalose-induced lysosomal changes and TFEB activation50%
mentions🧫Trehalose-induced lysosomal membrane permeabilization and TF50%
mentions🧫Microglial TREM2 Agonist In Vivo Efficacy50%
mentions🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim50%
mentions🧫TREM2 Function in Alzheimer's Disease — From Risk Varia50%
mentions🧪Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuro50%
mentions🧪APOE-Dependent Autophagy Restoration50%
mentions🧪APOE-TREM2 Interaction Modulation50%
mentions🧪TREM2-Mediated Selective Aggregate Clearance Pathway50%
mentions🧪TREM2-Dependent Microglial Senescence Transition50%
mentions🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia50%
mentions🧪Astrocyte-Mediated Neuronal Epigenetic Rescue50%
mentions🧪The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction50%
mentions🧪TFEB-PGC1α Mitochondrial-Lysosomal Decoupling50%
related🔬What are the mechanisms underlying synaptic pruning by micro50%
related🔬Investigate prion-like spreading of tau pathology through co50%
related🔬What are the mechanisms underlying tdp-43 phase separation t50%
related🔬What are the mechanisms underlying blood-brain barrier trans50%
related🔬What are the mechanisms underlying synaptic pruning by micro50%
related🔬Investigate prion-like spreading of tau pathology through co50%
related🔬How does metabolic reprogramming (glucose metabolism shifts,50%
mentions🧫Epigenetic Regulation Dysfunction in Alzheimer's and Pa44%
mentions🧫Microtubule domain analysis in adult axons44%
mentions🧫Tau depletion effects on neuronal development in primary cul44%
mentions🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers44%
mentions🔬What are the mechanisms underlying tdp-43 phase separation t40%
mentions🔬What are the mechanisms underlying blood-brain barrier trans40%